AIDS Crisis Recognized
In June 1981, the US Centers for Disease Control and Prevention published a short report in its Morbidity and Mortality Weekly Report describing five young men in Los Angeles who had developed a rare lung infection, Pneumocystis pneumonia. Within weeks, doctors in New York and California reported unusual cases of an aggressive cancer, Kaposi's sarcoma, in similar patients. These reports marked the first formal recognition of what became known as AIDS, a disease that would grow into one of the deadliest pandemics in modern history, with deaths estimated at roughly 40 million over the following decades.
The cases were startling because both conditions normally appear only in people with severely weakened immune systems. Physicians noticed that most patients were gay men, and early on the condition was informally called "gay-related immune deficiency," a label that proved misleading and stigmatizing. Cases soon appeared among injection drug users, people with hemophilia who had received blood products, Haitian immigrants, and infants born to affected mothers. By 1982 the CDC had adopted the name Acquired Immune Deficiency Syndrome, and it became clear that the cause was an infectious agent transmitted through blood, sexual contact, and from mother to child.
In 1983, researchers at the Pasteur Institute in France, including Françoise Barré-Sinoussi and Luc Montagnier, identified a retrovirus linked to the disease. American scientist Robert Gallo's laboratory also contributed key work, and a dispute over credit followed. The virus was later named human immunodeficiency virus, or HIV. A blood test arrived in 1985, allowing screening of blood supplies and diagnosis of infection. Later genetic studies traced HIV to simian viruses in central Africa, with the jump to humans occurring in the early twentieth century, decades before the disease was recognized.
The early years were marked by fear, discrimination, and slow government response, particularly in the United States, where activists criticized official inaction. Groups such as ACT UP pushed for faster drug research and wider access to treatment. The first antiretroviral drug, zidovudine (AZT), was approved in 1987, but it offered limited benefit alone. The turning point came in the mid-1990s with combination antiretroviral therapy, which transformed HIV from a near-certain death sentence into a manageable chronic condition for those who could obtain the drugs.
Access remained deeply unequal. Sub-Saharan Africa bore the heaviest burden, and millions died before affordable generic medicines and international programs, including the Global Fund and the US PEPFAR initiative in the early 2000s, expanded treatment. Today, effective therapy can suppress the virus so that it cannot be transmitted, and preventive medication is available, yet there is still no cure or widely available vaccine. The AIDS crisis reshaped medical research, patient advocacy, and public health, and its lessons continue to inform responses to new epidemics.